

In the Claims:

Please add new claims 13-19.

Please amend claims 9 and 12 to read as follows:

E1
SUB
F1 9. (Twice Amended) An antibody fragment according to claim 12 covalently attached to one or more reporter molecules.

12. (Amended) A polymer modified monovalent antibody fragment, wherein said fragment comprises a heavy chain and a light chain, wherein

said heavy chain comprises a VH domain covalently linked at its C-terminus to a CH1 domain extended to provide a hinge region domain, said hinge region domain comprising not more than one cysteine residue;

E2
SUB
F1 said light chain comprising a VL domain, which is complementary to the VH domain, covalently linked at its C-terminus to a CL domain;

where not more than one polymer molecule is covalently attached to the monovalent antibody fragment, said polymer molecule is linked to said cysteine residue in said hinge region domain of said heavy chain;

and wherein said polymer is an optionally substituted, straight or branched chain polymer selected from the group consisting of poly(ethylene glycol), poly(propylene glycol), poly(vinyl alcohol) and derivatives thereof.

13. (New claim) An antibody fragment according to claim 12 covalently attached to one or more effector molecules.

E3
SUB
F1 14. (New claim) The fragment of claim 13 wherein the effector molecule is an antineoplastic agent, toxin, enzyme, nucleic acid, radionuclide, or chelated metal.